JAMIE ROGERS: Open Payments
NPI 1396081360 · MENIFEE, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,143 in 34 payments from 11 companies in 2025. Trend: 2023 $17 · 2024 $122 · 2025 $1,143
Food & beverage: $1,143
| Company | Payments | Amount |
|---|---|---|
| Amgen Inc. | 11 | $410 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 4 | $186 |
| Novo Nordisk Inc | 4 | $175 |
| Neurocrine BioSciences, Inc. | 2 | $140 |
| Lundbeck LLC | 5 | $70 |
| Corcept Therapeutics | 2 | $38 |
| GlaxoSmithKline, LLC. | 2 | $34 |
| Lilly USA, LLC | 1 | $30 |
| Otsuka America Pharmaceutical, Inc. | 1 | $22 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $21 |
Products named: Repatha, XIFAXAN, OTEZLA, INGREZZA, Ozempic, REXULTI, Korlym, TRELEGY ELLIPTA.
Industry payments across CA — which companies pay providers there.
